Week in Review: Luye Pharma to Raise $764 Million in Hong Kong IPO

Luye Pharma of China plans to raise as much as $764 million in a Hong Kong IPO next month after being taken private from the Singapore exchange in 2012; Fosun Pharma will invest $46.3 million in Nature's Sunshine Products, a US nutritional company, and together they will form a JV to distribute Nature’s Sunshine products in China; Cancer Genetics signed a LOI to acquire Gentris Corporation, a pharmacogenomics company that is building a lab in Shanghai; Verisante of Canada sold China rights for its cancer diagnostic device to an unnamed partner; Jiangsu Hengrui Medicine was approved by the FDA for US marketing of the chemotherapy oxaliplatin; and Bruker was cleared by the CFDA to market its microorganism-identification medical device in China. More details…. Stock Symbols: (SHA: 600196; HK: 2196) (NSDQ: NATR) (NSDQ: CGIX) (OTCQX: VRSEF; TSX-V: VRS) (SHA: 600276) (NSDQ: BRKR) Share this with colleagues: // //